
Get exclusive money-saving offers and guides
Straight to your inbox
Updated
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Immutep Limited is a biotechnology business based in Australia. Immutep shares (IMM) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Immutep has a trailing 12-month revenue of around $13.7 million..
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.1 - $44.5 |
---|---|
50-day moving average | $4.3703 |
200-day moving average | $1.182 |
Target price | $0.08 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.006 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$0.415 on 2021-01-25
1 week (2021-01-18) | -7.78% |
---|---|
1 month (2020-12-24) | 6.41% |
3 months (2020-10-23) | 59.62% |
6 months (2020-07-24) | 97.62% |
1 year (2020-01-24) | 45.61% |
---|---|
2 years (2019-01-25) | 39.26% |
3 years (2018-01-25) | 74.08% |
5 years (2016-01-25) | -12.94% |
Revenue TTM | $13.7 million |
---|---|
Gross profit TTM | $-6,656,699 |
Return on assets TTM | -21.62% |
Return on equity TTM | -46.69% |
Profit margin | -98.03% |
Book value | 0.068 |
Market capitalisation | $262.4 million |
TTM: trailing 12 months
We're not expecting Immutep to pay a dividend over the next 12 months.
Immutep 's shares were split on a 1:10 basis on 5 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immutep shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Immutep shares which in turn could have impacted Immutep 's share price.
Over the last 12 months, Immutep 's shares have ranged in value from as little as $0.1 up to $44.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Immutep 's is 1.3258. This would suggest that Immutep 's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
From the best lip exfoliator to the top product for the body, we rounded up the seven best exfoliators you can get in Australia right now.
From the best overall face moisturiser for dry skin to the best body moisturiser, hand moisturiser and tinted moisturiser for dry skin, these are the best 7 moisturisers for dry skin you can buy in Australia right now.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.